1 Min Read
Aug 29 (Reuters) - Paradigm Biopharmaceuticals Ltd:
* FY net loss for the period attributable to members $4.3 million
* FY revenue from continuing activities $1.8 million, up 32.62 percent Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.